1 High prevalence of hepatitis B and HIV among women survivors of sexual violence in South Kivu

2 province, eastern Democratic Republic of Congo

3 Hepatitis B and HIV among women survivors of sexual violence in South Kivu province

- 4 Parvine Basimane Bisimwa^{1,2,3,4,5}, Dieudonné Bihehe Masemo^{2,3}, Aline Kusinza Byabene^{2,3}, Georges
- 5 Kikuni Besulani^{2,3}, Théophile Kashosi Mitima⁴, Cadeau Mugisho Matabishi³, Bienfait Mitima Misuka⁴,
- 6 Omari Mukanga⁶, Jean Paulin Mukonkole^{2,3}, Jean Bisimwa Nachega^{7,8,9}, Denis Mukwege^{2,5}, Narcisse
- 7 Patrice Joseph Komas^{1*}.
- 8 ¹Viral Hepatitis Laboratory, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African Republic.
- 9 ²Faculty of Medecine, Université Evangélique en Afrique (UEA), Bukavu, Democratic Republic of Congo
- 10 ³Departments of Internal Medicine, Panzi Hôpital General Referral Hospital, Bukavu, Democratic
- 11 Republic of Congo
- 12 ⁴Molecular Biology Laboratory, Université Evangélique en Afrique (UEA), Bukavu, Democratic Republic 13 of Congo
- 14 ⁵International Center Advanced for Research and Training (ICART)/Panzi Fondation, Bukavu,
- 15 Democratic Republic of Congo
- 16 ⁶Statistical Service, VVS-Panzi General Referral Hospital, Bukavu, Democratic Republic of Congo
- 17 ⁷Departments of Epidemiology, Infectious Diseases and Microbiology, University of Pittsburgh School of
- 18 Public Health, Pittsburgh, PA, USA
- 19 ⁸Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public 20 Health, Baltimore, MD, USA
- 21 ⁹Department of Medicine, Stellenbosch University Faculty of Medicine and Health Sciences, Cape 22 Town, South Africa

23 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

*Corresponding author: npkomas@yahoo.fr /narcisse.komas@pasteur-bangui.cf (NPJK) 24

26 Abstract

29

Introduction: Limited data are available on the prevalence rates of hepatitis B and acquired
 immunodeficiency syndrome (AIDS) among women survivors of sexual violence (WSSV) in South Kivu

province, in the eastern part of the Democratic Republic of Congo (DRC), where armed conflicts persist.

30 Here, we aimed to assess the prevalence of these two diseases in this vulnerable local population.

Methods: A total of 1002 WSSV, aged from 18 to 70 years old were enrolled from May 2018 to May 2020 at three one-stop centers, set up at the Panzi, Mulamba and Bulenga hospitals. Blood samples were collected and tested for hepatitis B virus (HBV) and human immunodeficiency virus (HIV) antigens and antibodies using enzyme-linked immunoassay (ELISA) methods. Viral load quantification for HBV and HIV were performed using the GeneXpert.

36 **Results:** For HBV, overall prevalence was 8.9% (95% CI [7.2–10.8%]), 32.1% [29.3–35.0%], and 14.5% 37 [12.3–16.8%] for HBsAg, anti-HBc and anti-HBs antibodies, respectively. Among the 89 HBsAg-positive 38 patients, 17 (19.1%) were HBeAg-positive. The mean age was 40.57±14.99 years in the HBsAg-39 positive group (p=0.025). Risk factors for HBV infection were age (\geq 35 years) (AOR=1.83 [1.02-3.32]; 40 p=0.041), having no schooling (AOR=4.14 [1.35-12.62]; p=0.012) or only primary school-level 41 (AOR=4.88 [1.61-14.75]; p=0.005), and multiple aggressors (AOR=1.76 [1.09-2.84], p=0.019). The 42 prevalence of HIV was 4.3% [3.1–5.7%]. HIV/HBV co-infection occurred only in 5 individuals (0.5%). 43 The HBV viral load was detectable (>2,000 copies/mL) in 61.8% of HBsAg-positive subjects and 64.8% 44 HIV-positive subjects had a high viral load (>1,000 copies/mL).

45 Conclusion: This study revealed a high prevalence of HBV and HIV infections among WSSV in South
46 Kivu. These results highlight the urgent need for systematic screening of HBV and HIV by integrating
47 fourth-generation ELISA tests in HIV and HBV control programs.

48 Key words: Survivors of sexual violence; HBV infection; HIV infection; HBV and HIV co-infection;

49 South Kivu; Democratic Republic of Congo; DRC.

50

51 Introduction

52 Sexually transmitted infections (STIs) constitute a heavy public health burden in many developing 53 countries, including the Democratic Republic of Congo (DRC). Two STIs, i.e. those caused by hepatitis 54 B virus (HBV) and human immunodeficiency virus (HIV), affect approximately 2 billion and 37.7 million 55 people worldwide, respectively [1,2]. HBV is one of the leading infectious killers globally, with 887,000 56 deaths due to HBV-associated hepatic sequelae such as acute hepatitis, liver cirrhosis, and liver cancer 57 or hepatocellular carcinoma (HCC), recorded worldwide in 2015 [1]. Its prevalence is highest in the 58 Western Pacific and African regions, where respectively 6.2% and 6.1% of the adult population is 59 infected [3]. The World Health Organization (WHO) has classified the DRC as an intermediate 60 endemicity area, with 5 to 7.99% of HBV infection [1.3]. In endemicity areas, HBV infection is usually 61 transmitted from mother to child at delivery or by horizontal transmission among children, especially 62 during the first five years [3-5]. It is also transmitted by sexual intercourse through vaginal and seminal 63 secretions, by tattooing and piercing with non-sterilized equipment, by blood exposure accidents, and by 64 other infected body fluids such as saliva [1.3.4].

65 The Joint United Nations Program on HIV/AIDS (UNAIDS) and WHO reports show that among the 37.7 66 million people living with HIV worldwide, adults (36.0 million) predominate. Of these infected adults, 67 women, and girls (53%) were the most infected groups in 2020 [2,5,6]. According to the same reports, 68 HIV infection was responsible for around 680,000 deaths worldwide in 2020, compared with 1.3 million 69 in 2010 and 1.9 million in 2004, with a significant decrease (53%) in women and girls [2,6]. However, 70 despite the decrease in HIV incidence and associated mortality worldwide with increased access to 71 potent antiretroviral therapy, incidence rates can nonetheless be alarming in post- or armed conflict 72 countries where sexual violence is used as weapon of war. In 2020, the WHO estimated that 30% of 73 women have been raped, representing a vulnerable group that may be at high risk of HIV infection, 74 particularly adolescent girls, and young women [6]. Sexual violence has become endemic in the eastern

DRC, particularly in South Kivu [7]. From September 1999 to March 2021, the teams from the Panzi Hospital have taken care of over 68,774 women survivors of sexual violence (WSSV), among whom only 12% were admitted in less than 72 h and 6% with pregnancies resulting from rape (Panzi Foundation Report 2021).

79 The South Kivu province, where this study was undertaken, is rife with frequent sexual violence 80 perpetrated on women due to recurrent armed conflicts, especially in rural areas [7]. Furthermore, 81 sporadic cases of sexual violence are reported in the city of Bukavu [8]. These situations may increase 82 sexual transmission of HBV and HIV in this area due to their transmission mode. However, few studies 83 have been conducted on the prevalence of HBV and HIV infections or the burden of HIV/HBV co-84 infection in South Kivu. This study aims to determine the prevalence of and the factors associated with 85 HBV and HIV infections among WSSV enrolled at one-stop centers in South Kivu. This information is 86 important for predicting the risk of HBV/HIV co-infection and for setting up suitable management of the 87 infections.

88 Methods

89 Study design, setting, and population

90 This is a cross-sectional study conducted from May 2018 to May 2020. Participants were recruited from 91 urban and rural one-stop centers of the Panzi Foundation, including the Panzi General Referral 92 Hospital, the Mulamba Hospital Center, and the Bulenga Hospital Center. The Panzi Hospital is the 93 reference center for the health sector in the city of Bukavu. This hospital specializes in several medical 94 areas and today, it is a treatment center for victims and survivors of sexual violence. The hospital 95 receives 5 to 7 female victims of sexual violence every day through the Panzi Foundation, within which 96 the "one-stop center" model of care was developed by Prof [8]. Denis Mukwege, winner of the 2018 97 Nobel Peace Prize. This model allows victims and survivors of sexual violence to receive holistic care 98 (medical, psychosocial, legal, and socio-economic reintegration) and other services to restore their 99 healthy life needs [8]. Panzi Hospital has partnered up with other one-stop centers, such as the

- 100 Mulamba Hospital Center, located at about 70 km southwest of Bukavu in the rural area of Walungu,
- and the Bulenga Hospital Center, located near Goma, 165 km from Bukavu.

102 Eligibility criteria

The study population included all women aged 18 years and over with a history of sexual violence of more than 3 months, who received treatment and medical care at one of the above-mentioned one-stop centers. They were admitted for management of various complications related to sexual violence including medical, surgical, gynecological, and social care. A total of 1002 women participants were included in this study. The sample size was determined based on HBV prevalence (5.0%) in the DRC [9], with a precision of ±3% at a 95% confidence level.

109 Specimen and data collection

110 At each one-stop center, prior to administering a questionnaire, an information session was offered to 111 WSSV providing clear explanations, in the local language where necessary, using readily 112 understandable terms about HBV and HIV-related diseases. An informed-consent form was then signed 113 by each participant and the collected information remained anonymous. Sociodemographic and clinical 114 variables were recorded. Clinical variables mainly involved patient history of jaundice, vaccination, 115 transfusion, scarification, tattoo, traditional excision, number of sex partners before and after sexual 116 violence, number of aggressors, and the occurrence of pregnancy; sociodemographic variables included 117 age, origin, tribe, level of schooling, religion, marital status, and occupation. Approximately 10 mL of 118 venous blood was collected in an EDTA tube for rapid screening HIV and HBV tests and results were 119 reported to participants immediately after screening. In addition, dried blood spots (DBS) were prepared 120 in the Medical Research Laboratory (MRL) at the Université Evangélique en Afrique (UEA) in Bukavu by 121 spotting a drop of whole blood on Whatman filter paper. This sample preparation was followed by drying 122 and sealing the DBS in plastic bags for storage at room temperature in presence of a desiccant until 123 transferred to the Viral Hepatitis Laboratory at the Institut Pasteur de Bangui in the Central African 124 Republic (CAR) for further analysis.

125 Serological assays

126 The HBV markers were detected using an enzyme-linked immunosorbent assay (ELISA) provided in 127 DiaSource kits (DiaSource ImmunoAssays S.A., Belgium) according to the manufacturer's instructions. 128 All samples were tested for the hepatitis B surface antigen (HBsAg), and hepatitis B core antibody (anti-129 HBc). A confirmatory ELISA test of HBsAg was used for HBsAg-positive samples. HBsAg-negative 130 samples were screened for the HBs antibody (anti-HBs Ab) and HBsAg-positive samples were screened 131 for the hepatitis B e antigen/antibody (HBeAg/anti-HBe Ab) and anti-HBc IgM antibodies. The Murex 132 ELISA kit, (DiaSorin S.p.A., Italy) was used for quality control and confirmation of all positive samples. 133 The presence of HIV was detected using the HIV Ab/Ag Combo ELISA kit (DiaSource ImmunoAssays 134 S.A.) according to the manufacturer's instructions. After serological testing, all HBV- and HIV-positive 135 samples were transported to the Panzi Hospital laboratory for viral load quantification. This viral load 136 detected HBV DNA and HIV RNA in the blood of patients using Cepheid GeneXpert kits Xpert® HBV 137 Viral Load and Xpert® HIV-1 Qual for HBV and HIV, respectively by following the manufacturer's

138 recommendations.

139 Statistical analysis

Data were collected from a structured survey questionnaire, compiled into a Microsoft Excel 2016 spreadsheet, and then imported into Stata SE 14.0 (Stata Corp LP, College Station, Texas, USA) for clean-up and analysis.

To describe the data, we computed means and their standard deviations (SDs) and medians with interquartile ranges (IQRs) for continuous variables, as appropriate. Categorical variables were summarized as frequencies and their percentages. To compare two means or medians, we used Student's *t*-test. To compare proportions, we used the Pearson chi-square test or the Fisher exact test for proportions less than or equal to 5. We constructed univariate and multivariate logistic regression models to assess factors associated with HIV-positive and HBV-positive status among WSSV. Variables with a *p*-value 0.2 or lower were included in the model.

The adjusted odds-ratios (AOR) and their 95% confidence intervals (CI) were derived to measure the strength of the association between the variables. All *p*-values were two-sided, and *p*-values less than 0.05 indicated statistical significance.

153 Ethical approval and consent to participate

154 This study obtained approval from the ethics committee of the Catholic University of Bukavu 155 (UCB/CIE/NC/008/2016) reviewed 2019 the national health ethics committee in by 156 (CNES001/DPSK/124PP/2019) and from the ethics and scientific committees of the University de 157 Bangui (22/UB/FACSS/CSVPR/19). Written informed consent was signed by the participant in the 158 interest of knowing her serological status to consider early treatment in case of a positive result, as well 159 as for her participation in the study. The preliminary results for HBV and HIV screening were given to 160 participants immediately after screening and 3 weeks later for definitive result. HIV- and HBV-positive 161 cases were referred to the Panzi Hospital for medical care.

162 Results

163 Sociodemographic and seroprevalence of HBV and HIV infection among survivors of sexual 164 violence

The average age of the study participants was 37.85 ± 15.11 years and most were 35 years old and older (53.9%). The majority were married (47.7%), Protestant (53.5%) and from rural areas (92.4%) (table 1). Of the 1002 participants, the prevalence rates of HBV markers were 8.9% (95% CI: [7.2 – 10.8%]), 32.1% [29.3–35.0%], and 14.5% [12.3–16.8%] for HBsAg, anti-HBc and anti-HBs antibodies, respectively. Of the 89 HBsAg-positive participants, 17 (19.1%) were also HBeAg-positive.

The mean age was 40.57 ± 14.99 years in the HB-positive group, statistically significantly higher than the overall mean age (*p*=0.025). Furthermore, participants aged 35 years and older were more frequently HBsAg-positive than those under 35 years (*p*=0.027). A statistical difference was observed in participants with no formal schooling or only or primary-school education (10.1 and 10.4%, respectively;

p=0.017) compared with those with secondary- or university-level education. However, there was no statistical difference in the prevalence of HBV infection according to marital status or occupation, despite the slightly higher number of infection cases among separated/divorced women and public sector workers (17.1 and 12.5%; p=0.064 and p=0.922, respectively). Participants from the Havu tribe showed higher prevalence compared with participants from other tribes (19.1%; p<0.001). Religion and geographic origin of participants were not statistically associated with HBsAg positivity.

Similarly, for the hepatitis B contact marker (anti-HBc), the 35+ age group had a high prevalence compared with the under-35 age group (37.8% vs. 25.5%; p<0.001). For anti-HBs antibodies, a statistical difference was also observed between the age groups, with higher immunization in the over-35 age group (17.4% vs. 11.1%; p=0.007) compared with those under 35 years of age.

A total of 43 of the 1002 participants (4.3% [3.1%-5.7%]) tested positive for HIV. The Fuliru tribe was more frequently associated with HIV infection than the other tribes (12.2%; *p*=0.018). Although HIV infection appeared high, it was not statistically significant among women aged 35 years and over (4.4%), with no schooling (4.9%), married (5.2%), public sector workers (12.5%), Catholic (5.1%), or from rural areas (4.4%) (Table 1). Regarding HBV-HIV co-infection, the prevalence was 0.5%.

189

190 Table 1. Sociodemographic characteristics and prevalence of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) among survivors of sexual

191 violence in South Kivu

Characteristics	Number	Number	%	HE	BsAg		Anti-HBc an	tibodies		Anti-HBs an	tibodies		HIV Ag/Ab		
			Positive (n)	%	p	Positive (n)	%	p	Positive (n)	%	p	Positive (n)	%	p	
Overall prevalence	1002	100	89(1002)	8.9		322(1002)	32.1		132(913)	14.5		43(1002)	4.3		
Age (years)															
<35	462	46.1	31(462)	6.7	0.027	118(462)	25.5	<0.001	48(431)	11.1	0.007	20(462)	4.3	0.957	
≥35	540	53.9	58(540)	10.7	-	204(540)	37.8	_	84(482)	17.4	_	23(540)	4.4	_	
Schooling level															
No schooling	616	61.5	62(616)	10.1	0.017	218(616)	35.4	<0.001	84(554)	15.2	0.593	30(616)	4.9	0.587	
Primary	221	22.1	23(221)	10.4	-	71(221)	32.1	-	30(198)	15.2	-	6(221)	2.7	_	
Secondary	163	16.3	4(163)	2.5	-	31(163)	19.0	_	18(159)	11.3	_	7(163)	4.3	_	
University	2	0.2	0(2)	0.0	-	2(2)	100.0	-	0(2)	0.0	_	0(2)	0.0	_	
Marital status															
Single	235	23.5	17(235)	7.2	0.064	56(235)	23.8	0.015	24(218)	11.0	0.353	7(235)	3.0	0.507	
Married	519	51.8	44(519)	8.5	-	183(519)	35.3	-	75(475)	15.8	-	27(519)	5.2	_	
Separated/Divorced	76	7.6	13(76)	17.1	-	28(76)	36.8	-	11(63)	17.5		3(76)	3.9	_	
Widowed	172	17.2	15(172)	8.7	-	55(172)	32.0	-	22(157)	14.0	-	6(172)	3.5	_	
Occupation							<u> </u>								
No occupation	174	17.4	13(174)	7.5	0.922	55(174)	31.6	0.706	29(161)	18.0		6(174)	3.4	0.537	

Farmer	667	66.6	60(667)	9.0		222(667)	33.3		88(607)	14.5		32(667)	4.8	
School /Pupil/ Student	105	10.5	11(105)	10.5	_	28(105)	26.7		9(94)	9.6	0.323	3(105)	2.9	
Entrepreneur (trade)	48	4.8	4(48)	8.3	-	14(48)	29.2		6(44)	13.6		1(48)	2.1	-
Public sector worker	8	0.8	1(8)	12.5	-	3(8)	37.5	-	0(7)	0.0		1(8)	12.5	-
Tribe														
Shi	478	47.7	28(478)	5.8	<0.001	127(478)	26.6	0.009	61(450)	13.4		19(478)	4.0	0.018
Havu	184	18.4	35(184)	19.0		82(184)	44.6	-	23(149)	15.4		5(184)	2.7	
Fuliru	82	8.2	7(82)	8.5	-	28(82)	34.1	-	9(75)	12.0		10(82)	12.2	
Lega	74	7.4	7(74)	9.4	-	24(74)	32.4	1	7(67)	10.4	0.680	4(74)	5.4	-
Bembe	45	4.5	2(45)	4.4	-	18(45)	40.0	1	10(43)	23.3		1(45)	2.2	-
Tembo	54	5.4	5(54)	9.3	-	16(54)	29.6	-	7(49)	14.3		1(54)	1.9	
Other	85	8.5	5(85)	5.9	-	27(85)	31.8	1	15(80)	18.7		3(85)	3.5	
Religion														
No religion	7	0.7	1(7)	14.3	0.071	4(7)	57.1	0.379	1(6)	16.7	0.703	0(7)	0.0	0.632
Catholic	429	42.8	40(429)	9.4	-	139(429)	32.4	-	57(389)	14.7	-	22(429)	5.1	
Muslim	5	0.5	2(5)	40.0	-	3(5)	60.0		0(3)	0.0	-	0(5)	0.0	
Protestant	536	53.5	42(536)	7.8	-	167(536)	31.2		73(494)	14.8	-	21(536)	3.9	
Other	25	2.5	4(25)	16.0	_	9(25)	36.0	-	1(21)	4.8	_	0(25)	0.0	
Geographic area		<u> </u>			1			1	1		1	1		
Rural	926	92.4	79(926)	8.5	0.173	296(926)	32.0	0.687	120(847)	14.2	0.365	41(926)	4.4	0.458
Urban	76	7.6	10(76)	13.2	-	26(76)	34.2	-	12(66)	18.2	_	2(76)	2.6	-

192 Ab, antibodies; Ag, antigens; HBs Ag, hepatitis B surface antigens; HBc, hepatitis B core

193 Clinical history, and HBV and HIV infections among survivors of sexual violence

- 194 For HBV infection, a statistically significant association was found between the presence of HBsAg and multiple aggressors (11.0%; *p*=0.022). The absence of
- HBV vaccination was statistically associated with the presence of HBsAg (*p*=0.011). There was no statistical difference between the prevalence of HBV infection
- 196 and other factors. However, participants with a history of tattoo, traditional genital excision, multiple sexual partners before sexual violence and current multiple
- 197 sexual partners had slightly higher prevalences of HBV (10.3%, 10.6%, 10.0%, and 9.1%, respectively) (Table 2).
- 198 For HIV infection, no association was found with those factors.

199

Table 2. Clinical history and hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections among women survivors of sexual violence 201

Characteristics	Number	HBsAg			HIV Ag/Ab		
	N(%)	Positive n(%)	Negative n(%)	p	Positive n(%)	Negative n(%)	p
Pregnancy							
Yes	61(6.1)	5(8.2)	56(91.8)	0.846	2(3.3)	59(96.7)	0.687
No	941(93.9)	84(8.9)	857(91.1)	_	41(4.4)	900(95.6)	-
History of jaundice							
Yes	23(2.3)	2(8.7)	21(91.3)	0.975	1(4.3)	22(95.7)	0.989
No	979(97.7)	87(8.9)	892(91.1)		42(4.3)	937(95.7)	-
Vaccination							
Yes	6(0.6)	0(0.0)	6(100.0)	0.011	0(0.0)	6(100.0)	0.603
No	996(99.4)	89(8.9)	907(91.1)	_	43(4.3)	953(95.7)	-
Transfusion							
Yes	47(4.7)	1(2.1)	46(97.9)	0.095	1(2.1)	46(97.9)	0.453
No	955(95.3)	88(9.2)	867(90.8)	_	42(4.4)	913(95.6)	_
Condom use							
Never	974(97.2)	88(9.0)	886(91.0)	0.316	41(4.2)	933(95.8)	0.450
		1(3.5)	27(96.5)	_	2(7.1)	26(92.9)	_

Yes	39(3.9)	4(10.3)	35(89.7)	0.758	2(5.1)	37(94.9)	0.793
No	963(96.1)	85(8.8)	878(91.2)		41(4.3)	922(95.7)	
Scarification	I						
Yes	28(2.8)	2 (7.1)	26(92.9)	0.743	0(0.0)	28(100.0)	0.256
No	974(97.2)	87(8.9)	887(91.1)		43(4.4)	931(95.6)	
Traditional excision							
Yes	123(12.3)	13(10.6)	110(89.4)	0.483	4(3.3)	119(96.7)	0.544
No	879(87.7)	76(8.6)	803(91.4)		39(4.4)	840(95.6)	
Multiple sex partners be	fore sexual violence						
Yes	609(60.8)	61(10.0)	548(90.0)	0.174	28(4.6)	581(95.4)	0.633
No	393(39.2)	28(7.1)	365(92.9)		15(3.8)	378(96.2)	
Current multiple sex par	tners						
Yes	536(53.5)	49(9.1)	487(90.9)	0.824	20(3.7)	516(96.3)	0.354
No	466(46.5)	40(8.6)	426(91.4)		23(4.9)	443(95.1)	
Number of aggressors							
Single	521(52.0)	36(6.9)	428(93.1)	0.022	21(4.0)	499(96.0)	0.672
Multiple	481(48.0)	53(11.0)	428(89.0)		22(4.6)	459(95.4)	

202 Ab, antibodies; Ag, antigens; HBs Ag, hepatitis B surface antigens; HBc, hepatitis B core; virus; HIV, human immunodeficiency virus.

203 Risk factors and HBV infection

- 204 The results showed that HBs-positive status was associated with women aged 35 or older (AOR=1.83
- 205 [1.02–3.32]; *p*=0.041), having no schooling (AOR=4.14 [1.35–12.62]; *p*=0.012) or primary schooling only
- 206 (AOR=4.88 [1.61–14.75]; p=0.005), being part of the Havu tribe (AOR=4. 84 [1.08–21.64]; p=0.039),
- 207 and multiple aggressors (AOR=1.76 [1.09–2.84]; *p*=0.019) (Table 3).
- 208 For HIV, after adjustment of the logistic regression model, we did not find any statistically significant
- associations between the risk factors studied and HIV status among WSSV (*p*>0.05).
- 210
- 211 Table 3. Univariate and multivariate analysis of factors associated with hepatitis B status among
- 212 survivors of sexual violence

Characteristics	COR [95% CI]	p-Value	AOR [95% CI]	<i>p</i> -value
Age group (years)	I	I		
<35	1 (reference)		1 (reference)	
≥35	1.67 [1.06–2.63]	0.027	1.83 [1.02–3.32]	0.041
Marital status				
Single	1 [reference]		1 [reference]	
Married/Homemaker	1.18 [0.66–2.12]	0.562	0.93 [0.47–1.85]	0.848
Separated/Divorced	2.64 [1.21–5.74]	0.014	2.15 [0.84–5.47]	0.107
Widowed	1.22 [0.59–2.52]	0.582	0.74 [0.28–1.96]	0.547
Schooling level				
None	4.44 [1.59–12.41]	0.004	4.14 [1.35–12.62]	0.012
Primary	4.61 [1.56–13.62]	0.006	4.88 [1.61–14.75]	0.005
Secondary	-	-	-	-
University	1 (reference)		1 (reference)	
Religion	1			
None	1 (reference)			
Catholic	0.61 [0.07–5.25]	0.659	-	-
Muslim	4.00 [0.25–63.95]	0.327	_	

Protestant	0.51 [0.59–4.33]	0.538	-	-
Other	1.14 [0.10–12.24]	0.912	-	-
Blood transfusion				
No	1 (reference)		1 (reference)	
Yes	0.21 [0.29–1.57]	0.130	0.19 [0.02–1.45]	0.110
Aggressors				
Single	1 (reference)		1 (reference)	
Multiple	1.66 [1.07–2.59]	0.023	1.76 [1.09–2.84]	0.019
Tribe				
Bembe	1 (reference)		1 (reference)	
Fuliru	2 [0.39–10.09]	0.398	2.25 [0.43–11.70]	0.334
Havu	5.05 [1.16–21.85]	0.030	4.84 [1.08–21.64]	0.039
Lega	2.24 [0.44–11.32]	0.327	2.68 [0.51–14.03]	0.241
Shi	1.33 [0.30–5,80]	0.698	1.42 [0.31–6.34]	0.642
Tembo	2.19 [0.40–11.89]	0.362	2.89 [0.51–16.32]	0.228
Other	1.34 [0.25–7.21]	0.731	1.56 [0.28-8.72]	0.609
Use of condoms				
Yes	1 (reference)		1 (reference)	
No	2.68 [0.36–19.97]	0.336	1.84 [0.22–14.75]	0.565

*COR: Crude odds ratio; **AOR: Adjusted odds ratio. In this table, we present the crude and adjusted 213

214 odds ratios.

215

216 Level of HBV and HIV viral loads in positive participants

217 Out of a total of 89 HBsAg-positive samples, the mean viral load was 4949423.89 ± 22250009 IU/mL; 218 38.2% of the samples had an undetectable viral load, 39.3% a low viral load (<2000 IU/mL), and 22.5% 219 a high viral load (≥2000 IU/mL). For HIV, for those participants who tested positive for the first time, the 220 average viral load was 227924.24 ± 734065.81 copies/mL (table 4. The distribution of the HIV viral load

- showed a low (<1000 copies/mL) viral load for 35.2% of the patients and a high (≥1000 copies/ml) for
- 222 64.8% (Table 4).
- 223 Table 4. HBV and HIV viral load results in participants who tested positive

Virological parameters	Number	%
HBV DNA viral load (UI/mL)	N=89	
Mean±SD	4949423.89 ± 22250009	
Undetectable	34	38.2
< 2000	35	39.3
≥ 2000	20	22.5
HIV RNA viral load (copies/mL)	N=34	
Mean±SD	227924.24 ± 734065.81	
< 1000	12	35.2
≥ 1000	22	64.8

224

225 Discussion

226 In this study, the overall prevalence of HBsAg was 8.9% [7.2%-10.8%] and 32.1% [29.3%-35.0%] for 227 anti-HBc antibody. These results demonstrate the high burden of HBV in this vulnerable population. The 228 prevalence of HBV infection varies across regions and different types of population in the DRC [9]. 229 Previous studies on HBV infection have focused on blood donors in DRC different regions, reporting 230 HBsAg prevalence rates ranging from 6.8% to 9.2%, but in other population groups, prevalence seems 231 to be much lower [10-17]. For example, one study in the Maniema province reported a prevalence of 232 5.9% for HBsAg in pregnant women [18]. But the results of 2013-2014 Demographic and Health Survey 233 on the general population showed a prevalence of 3.3% in adults and 2.2% in children [9]. In contrast, 234 an HBsAg prevalence of 24.6% was reported on samples from 2003 to 2012 in the yellow fever 235 surveillance program from patients with acute febrile jaundice and suspected yellow fever [19].

236

The difference in hepatitis B prevalence rates in these different regions of the DRC can likely be attributed to the exposure to different risk factors according to population type, and probably arises from the absence of a viral hepatitis control and prevention program, as well as the fact that hepatitis B vaccination is limited to infants only. This variation in prevalence is also found in sub-Saharan Africa, where the rate of HBV infection, which is often very high, also varies with the country, the studied populations, and the used techniques [20-37]. For example, the overall prevalence of 42.3% for anti-HBc antibody with 15.5% for HBsAg in students with high sexual activity in Bangui [23].

244 Our investigation also revealed that 14.5% of the study population shows anti-HBs antibodies. Of the 245 participants with this immunization marker, only 11.4% had a history of hepatitis B vaccination when 246 tested within 72 h of sexual violence, and 88.6% had no history of previous hepatitis B vaccination. In 247 the latter, the total anti-HBc antibody was present, clearly demonstrating that they had been in contact 248 with the virus itself. An association was found between the rate of immunization against HBV infection 249 and the over-35 years age group. Therefore, it is difficult to demonstrate precisely when the infection 250 was acquired with respect to sexual abuse but given the high proportion of antibody detection in older 251 patients, the hypothesis of infection acquired in conjunction with sexual abuse is highly plausible. 252 Unfortunately, the antibody titer was not determined in this study. The anti-HBs antibody titer for HBV 253 has been shown to decrease with age according to the age of the infection. Thus, the proportion of older 254 individuals with anti-HBs antibodies at ≥10 IU/mL may be low if the infection was acquired in childhood, 255 although they may nevertheless remain immunized against the infection [38].

256

For HIV infection, a prevalence of 4.3% [3.1%–5.7%] was found using fourth-generation ELISA tests. This prevalence is very high for this population category compared to that reported in a previous study among blood donors in Bukavu, which showed a low prevalence using rapid tests [11]. However, before the introduction of blood safety protocols in Kisangani, a prevalence of 4.7% was reported in this same

group [15]. Nevertheless, our study demonstrates, the high prevalence of HIV among sexually abused
 patients in South Kivu province.

263

The link between sexual violence against women and girls and HIV acquisition has been shown in several studies [39]. For example, in Uganda, 15–49 year-old women who had experienced sexual violence showed a 1.55 risk of HIV infection compared with those who had never experienced violence [40]. Similarly, in a study in South Africa, young women aged 15–24 years who reported multiple episodes of sexual violence were 1.51 more at risk to acquire HIV than women with one or no episodes of sexual violence; furthermore, an estimated 12% of new HIV infections could be attributed to sexual violence [41].

271

272 The same findings were reported in a cross-sectional study of 28,000 married women aged 15-49 years 273 in India, with a 4-fold higher risk of being HIV-positive among those who had experienced physical and 274 sexual violence by their partners than those who had not [42]. Although studies of HIV among women 275 who have experienced sexual violence are rare in the DRC, HIV prevalence is often very high (7.5%) 276 among female sex workers. This high prevalence contrasts with the overall HIV incidence in the general 277 population, which is estimated to have decreased from 2010 to 2020 from 1.2% to 0.7%, with a national 278 prevalence of 1.1% among women aged 15-49 years [43]. Furthermore, prevalence may be 279 underestimated considering the low rate of HIV testing in different groups and key populations, the use 280 of rapid tests in routine screening, and diagnoses that sometimes produce false negatives with a risk of 281 undetected HIV cases [44]. It has been well documented that women are two to four times more likely 282 than men to contract the virus through unprotected vaginal penetration [45-47]. Sexual abuse of women 283 and girls by one or more individuals is a direct risk factor for HIV transmission. The risk factors 284 associated with HIV infection observed in this study were as follows: age less than or equal to 25 years, 285 belonging to the Fulero tribe, occasional condom use, and number of assailants greater than or equal to

5. Women with a history of sexual assaults with more than 5 men in their lifetime had a higher frequency of HIV infection than those with fewer than 5 abusers. These results are consistent with studies that have shown that HIV is more prevalent among young women, sex workers, those with multiple sexual partners, those who have experienced physical or sexual violence, and those with low levels of education, but other factors such as poverty and early marriage are also implicated [47-50].

291

The main sources of HIV transmission vary by country. Risks found in sexual behavior include age at first intercourse [51], being sexually active, having multiple sexual partners, having unprotected sex, having unprotected sex with strangers [52], having sex during or after alcohol use [53], sexual violence [45], and transactional sex [54].

296

Addressing violence against women and gender equality has been identified by UNAIDS in the AIDS Investment Framework as essential for an effective response to the HIV epidemic [55]. Addressing gender-based violence (GBV) could have a significant impact on the HIV epidemic. Indeed, the national HIV program needs to recognize the following aspects: the direct and indirect implications of GBV in the mechanism of HIV dissemination, the importance of perpetrator dynamics, and that GBV reduction should be part of HIV prevention programs. Effective interventions are likely to include a structural component and a sexual violence awareness component.

304

305 Our study also revealed the prevalence of HBV/HIV co-infection that was 0.5%. This prevalence 306 appears to be low, because most studies on co-infection in sub-Saharan Africa always report high 307 prevalence rates [56]. Nevertheless, this prevalence varies across regions defined by HBV endemicity. 308 In regions such as sub-Saharan Africa and East Asia, where HBV prevalence is high, most HBV 309 infections occur perinatally or in early childhood through close household contact, medical procedures, 310 or cultural practices such as scarification or tattooing [57]. HBV infections are therefore more likely to

progress to chronic infections, resulting in a high prevalence of chronic HBV infection among young
 people at risk for sexual HIV [58].

313

314 HBV and HIV quantifications were performed on samples from our study populations using the 315 automated GeneXpert® system. The HBV viral load results showed that 77.5% had undetectable or low 316 viral load and 22.5% had a high viral load (≥2000 IU/mL). The 77.5% for whom the viral load was 317 undetectable or low were not likely to be put on antiviral therapy. However, the 22.5% with high viral 318 load should be treated therapeutically for infection, following further testing. This quantification test must 319 be made available and accessible to all patients in South Kivu to avoid shortages of antivirals or high 320 expenses related to the routine therapeutic management of anyone infected with HBV. Indeed, it is 321 known that more than 90% of infected adults spontaneously recover from acute viral hepatitis B, with 322 the disappearance of HBsAg after about 6 months [59,60]. Accurate measurement of HBV DNA levels 323 in the blood is essential to diagnose HBV infection, establish the prognosis of HBV-related liver disease, 324 and guide therapeutic decision-making to determine whether to initiate antiviral therapy and monitor the 325 virological response to antiviral therapy and emergence of resistance [61,62].

326

In resource-limited countries such as the DRC, the ability to determine the HBV viral load is a major issue for the therapeutic management of patients, because the technical facilities recommended by international guidelines are not available and/or accessible [63]. Quantifying HBV DNA in the blood is one of the essential tests to establish the prognosis of infection and support any therapeutic decisions [61,62].

For the 34 subjects in whom the HIV viral load was determined, 64.8% had a high viral load (≥1000 copies/mL) and 35.2% a low viral load (<1000 copies/mL). These viral loads show that HIV testing is still a real problem in this area of the world due to the inaccessibility of ELISA tests, which clearly have added value for the detection and diagnosis of HIV cases. The dearth of modern technical facilities</p>

336 contributes to the underestimation of HIV cases following the use of rapid tests. In this study, the 337 positive cases had a detectable HIV viral load, except for nine cases that were not tested due to the 338 insufficient amount of blood sample.

Our results clearly show the importance of using comprehensive tests for diagnosis of HBV and HIV in a vulnerable population group. However, not all tests to establish a complete diagnosis of liver diseases, such as transaminase and other complementary tests, were carried out, which thus constitutes a limitation of this study. Determining viral load remains an essential tool for the management of HBV infection.

344

345 **Conclusion**

This study shows a high prevalence of HBV and HIV infections among girls and women who have survived sexual violence in South Kivu, despite the low national prevalence of HIV and the intermediate endemicity of HBV infection in the DRC. In this study, the ELISA technique revealed that the prevalence of these infections is underestimated in South Kivu where girls and women have been exposed to sexual violence for many years due to repetitive wars. We suggest that actions to combat sexual violence against girls and women be integrated into strategies to combat HIV/AIDS and viral hepatitis B.

352

353 Contributors

JBN and NPJK supervised the study. PBB, JBN, and NPJK designed the study, wrote the first manuscript. PBB, TKM, CMM, and BMM contributed to the laboratory analyses. PBB and OM performed the statistical analyses. PBB, DBM, AKB, GKB and CMM contributed to the collection of clinical data and the medical management of patients. PBB, JNB, NPJK, JPM, DMM contributed to the critical revision of the manuscript. All authors contributed to the interpretation of the results, approved the final manuscript and accept responsibility for the decision to submit it for publication.

360

361 Funding

362 World Bank, grant number IDA H 980-ZR

363

364 **Declaration of interests**

- 365 The authors declare that they have no competing interests.
- 366

367 Data Sharing

All data were encoded and stored in an electronic database. Follow-up sheets were securely stored at the ICART/Panzi Foundation Research Center and accessible only to the principal investigator of the study. These data include epidemiological, clinical and therapeutic data. As these data are anonymized for the protection of participants according to the health ethics guidelines of our region, we cannot make them available to third parties.

373

374 Acknowledgements

375 The research presented in this publication was funded by the World Bank through the Panzi Foundation. 376 We would like to thank the viral hepatitis laboratory team at the Institut Pasteur de Bangui for all the 377 support received in conducting the laboratory analyses and facilitating the technical operations. This 378 work is a research collaboration between the Panzi Foundation and the Institut Pasteur de Bangui. We 379 are very grateful for the involvement of the director of the three 'One Stop Center' hospital. We would 380 also like to thank Mr Giscard Wilfried Koyaweda, Mr Rodrigue Balthazar Basengere Ayagirwe, Mr Ahadi 381 Bwihangane Birindwa, Mr Patrick Ntagereka Bisimwa for their contribution in the re-reading of this 382 manuscript.

383

384 References

385 1. WHO. Global hepatitis report, 2017. Geneva: World Health Organization, 2017. 386 (https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/, accessed July 21, 2021). 387 2. UNAIDS 2021 Global HIV & AIDS statistics (https://www.unaids.org/en/resources/fact-sheet, 388 accessed Dec 21, 2021). 389 3. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Geneva: 390 WHO. 2016. 391 4. World Health Organization. Global health sector strategy on viral hepatitis 2017–2021. Geneva:

392 WHO; 2017. Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep

World Health Organization. Global progress report on HIV, viral hepatitis and sexually
transmitted infections, 2021 Accountability for the global health sector strategies 2016–2021: actions for
impact. Available at: https://www.who.int/publications/i/item/9789240027077.

396 6. UNAIDS Global AIDS Update 2021— Confronting inequalities
397 (http://lawsandpolicies.unaids.org/ accessed Dec 21, 2021).

398 7. Mukwege DM, Nangini C. Rape with extreme violence: the new pathology in South Kivu,
399 Democratic Republic of Congo. PLoS Med. 2009 Dec;6(12):e1000204. doi:
400 10.1371/journal.pmed.1000204.

Mukwege D, Berg M. A Holistic, Person-Centred Care Model for Victims of Sexual Violence in
 Democratic Republic of Congo: The Panzi Hospital One-Stop Centre Model of Care. PLoS Med. 2016;
 13(10): e1002156. doi:10.1371/journal. pmed.1002156.

404 9. Thompson P, Parr JB, Holzmayer V, Carrel M, Tshefu A, Mwandagalirwa K, et al.
405 Seroepidemiology of Hepatitis B in the Democratic Republic of the Congo. Am J Trop Med Hyg. 2019
406 Jul;101(1):226-229. doi: 10.4269/ajtmh.18-0883

407 10. Kabamba NM, and Kabyla IB. Prévalence des marqueurs infectieux chez les donneurs de sang
408 en milieu rural. Cas de l'Hôpital General de Reference de Kamina]. Santé Publique. 2013; 25, 213-217

409 11. Namululi BA, Guerrieri C. and Dramaix M. Impact of Method of Re- cruitment of Blood Donors 410 on the Prevalence of HIV and HBV in Bukavu, DR Congo. Medicine et Santé Tropicales. 2012; 1, 69-74. 411 12. Kabinda JM, Miyanga SA, Misingi P, Ramarani SY. Les hépatites B et C chez les donneurs 412 bénévoles de sang et non rémunérés à l'Est de la République Démocratique du Congo. Transfusion 413 Clinique et Biologique. 2014 ; 21, 111-115. https://doi.org/10.1016/j.tracli.2014.04.001 414 13. Kabemba B, Kasendue E, Shiku M, Mukena T, Kasolva T, Kabingie N, et al. Seroprevalence of 415 Hepatitis B Virus Infection (HBsAg) in Rural Blood Donors, Moba, Tanganyika Province, Democratic

416 Republic of Congo (2014 to 2016). Open Access Library Journal. 2017; 4, 1-5. doi:
417 10.4236/oalib.1103434.

418 14. Michel KN and Benjamin IK. Prévalence des marqueurs infectieux chez les donneurs de sang
419 en milieu rural. Cas de l'hôpital général de référence de Ka mina. Santé Publique. 2013 ; 25, 213-217.

420 15. Batina A, Kabemba S and Malengela R. Infectious Markers among Blood Donors in Democratic
421 Republic of Congo. Revue Médicale de Bruxelles. 2007; 28, 145-149.

422 16. Kakisingi NC, Mukuku O, Matanda KS, Manika MM, Kyabu KV, Kasamba IE, et al. Profil
423 épidémiologique et séroprévalence des donneurs de sang aux cliniques universitaires de Lubumbashi,
424 République Démocratique du Congo. Pan African Medical Journal. 2016 ; 23, 175.

Mbendi NC, Longo-Mbenza B, Mbendi NS, Muyembe Tamfumu JJ, Situa KH and Vangu ND.
Prévalence du VIH et de l'Antigène HBS chez les donneurs du sang, risque résiduel de contamination
chez les receveurs du sang de Kinshasa-Est, République Démocratique du Congo. Médecine Tropicale.
2001; 61, 139-1423

Kabinda J, Akilimali T, Miyanga A, Donnen P et Michèle D. Hepatitis B, Hepatitis C and HIV in
Pregnant Women in the Community in the Democratic Republic of Congo. World Journal of AIDS. 2015;
5, 124-130. doi: 10.4236/wja.2015.52015,

432 19. Makiala-Mandanda S et al. High prevalence and diversity of hepatitis viruses in suspected
433 cases of yellow fever in the Democratic Republic of Congo. J Clin Microbiol. 2017 ; 55:1299–1312.

434 20. Amponsah-Dacosta E. Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan
435 Africa: Implications for elimination of viral hepatitis by 2030?. World J Gastroenterol. 2021;27(36):6025436 6038. doi:10.3748/wig.v27.i36.6025

437 21. Kafeero HM, Ndagire D, Ocama P, Kudamba A, Walusansa A, Sendagire H. Prevalence and
438 predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and
439 meta-analysis of epidemiological studies published from 2005 to 2020. Arch Public Health. 2021 Sep
440 18;79(1):167. doi: 10.1186/s13690-021-00686-1

Komas NP, Vickos U, Hübschen JM, Béré A, Manirakiza A, Muller CP, Le Faou A. Crosssectional study of hepatitis B virus infection in rural communities, Central African Republic. BMC Infect
Dis. 2013;13:286 doi: 10.1186/1471-2334-13-286

Komas NP, Baï-Sepou S, Manirakiza A, Léal J, Béré A, Le Faou A. The prevalence of hepatitis
B virus markers in a cohort of students in Bangui, Central African Republic. BMC Infect Dis. 2010 Jul
29;10:226. doi: 10.1186/1471-2334-10-226.

Akinbami AA, Oshinaike OO, Dosunmu OA, Adeyemo TA, Adediran A, Akanmu S, et al.
Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria.
BMC Res Notes. 2012 Mar 28;5:167. doi: 10.1186/1756-0500-5-167.

451 25. Tsague MK, Fotio AL, Bomgning CLK, Nguefack-Tsague G, Fopa F, Nguelefack TB.
452 Prevalence of viral and non-viral hepatitis in Menoua Division, West Region, Cameroon: a retrospective
453 hospital-based study. Pan Afr Med J. 2019 Apr 29; 32:212. doi: 10.11604/pamj.2019.32.212.16495.

Bigna JJ, Amougou MA, Asangbeh SL, Kenne AM, Noumegni SRN, Ngo-Malabo ET, Noubiap
JJ. Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis.
BMJ Open. 2017 Jun 30;7(6):e015298. doi: 10.1136/bmjopen-2016-015298

457 27. Xie, D.-D., Li, J., Chen, J.-T., Eyi, U.M., Matesa, R.A., Obono, M.M.O., et al. Seroprevalence of
458 Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus, and Treponema pallidum

Infections among Blood Donors on Bioko Island, Equatorial Guinea. PLoS ONE. 2015;10,
e0139947.https://doi.org/10.1371/journal.pone.0139947

461 28. Mongo-Onkouo A, Itoko OR, Boumba A, Niama F, Ahoui-Apendi C, Mimiesse MJ et al.

462 Seroprevalence and Molecular Biodiversity of Hepatitis B and Delta Virus Infections in the Republic of

463 Congo. Open Journal of Gastroenterology. 2018; 8, 448-454. doi: 10.4236/ojgas.2018.812046

464 29. Baseke J, Musenero M, Mayanja-Kizza H. Prevalence of hepatitis B and C and relationship to

465 liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic (JCRC), Kampala,

466 Uganda. Afr Health Sci. 2015 Jun;15(2):322-7. doi: 10.4314/ahs.v15i2.3

467 30. Lakoh S, García-Tardón N, Adekanmbi O, van der Valk M, Smith SJ, Grobusch MP. Prevalence

468 of viral hepatitis B and C in Sierra Leone-current knowledge and knowledge gaps: a narrative review.

469 Trans R Soc Trop Med Hyg. 2021 Oct 1;115(10):1106-1113. doi: 10.1093/trstmh/trab054.

470 31. Musa OL, B. M. Bussell S, Borodo MM, Samaila AA. Prevalence of hepatitis B virus infection in

471 Nigeria, 2000-2013: a systematic review and meta-analysis. Niger J Clin Pract. 2015;18(2):163–172.

472 doi: 10.4103/1119-3077.151035;

473 32. Ofori-Asenso R, Agyeman AA. Hepatitis B in Ghana: a systematic review & meta-analysis of 474 prevalence studies (1995–2015) BMC Infect Dis. 2016;16(1):130. doi: 10.1186/s12879-016-1467-5.;

475 33. Lingani M, et al. High prevalence of hepatitis B infections in Burkina Faso (1996-2017): a

476 systematic review with meta-analysis of epidemiological studies. BMC Public Health. 2018;18(1):551.

477 doi: 10.1186/s12889-018-5432-7.

478 34. Badawi M, Atif M, Mustafa Y. Systematic review and meta-analysis of HIV, HBV and HCV
479 infection prevalence in Sudan. Virol J. 15, 2018:148.

480 35. Hassan-Kadle PP, M. A. Osman MS, Ogurtsov. Epidemiology of viral hepatitis in Somalia:
481 Systematic review and meta-analysis study. World J Gastroenterol. 2018;24(34):3927. doi:
482 10.3748/wjg.v24.i34.3927.

483 36. Eboumbou Moukoko CE, Ngo Sack F, Essangui Same EG, Mbangue M, Lehman LG. HIV,
484 HBV, HCV and T. pallidum infections among blood donors and Transfusion-related complications
485 among recipients at the Laquintinie hospital in Douala, Cameroon. BMC Hematol. 2014 Feb 12;14(1):5.
486 doi: 10.1186/2052-1839-14-5.

487 37. Awili HO, Gitao GC, Muchemi GM. Seroprevalence and Risk Factors for Hepatitis B Virus
488 Infection in Adolescent Blood Donors within Selected Counties of Western Kenya. Biomed Res Int.
489 2020; 2020:8578172. Published 2020 Jun 17. doi:10.1155/2020/8578172.

King H, Xing J, Dean HD, Holtzman D. Trends in Prevalence of Protective Levels of Hepatitis B
Surface Antibody Among Adults Aged 18-49 Years With Risk Factors for Hepatitis B Virus InfectionUnited States, 2003-2014. Clin Infect Dis. 2020 Apr 15;70(9):1907-1915.doi: 10.1093/cid/ciz537.

493 39. Anderson N, Cockcroft A, Shea B. Gender-based violence and HIV: relevance for HIV 494 prevention in hyperendemic countries of southern Africa. AIDS. 2008;22(suppl 4):S73-S86.

495 40. Kouyoumdjian FG, Calzavara LM, Bondy SJ, et al. Intimate partner violence is associated with 496 incident HIV infection in women in Uganda. AIDS. 2013;27:1331-1338.

497 41. Jewkes R, Dunkle K, Nduna M, et al. Intimate partner violence, relationship power inequity, and
498 incidence of HIV infection in young women in South Africa: a cohort study. Lancet. 2010;376:41-48.

499 42. Decker MR, Seage GR, III, Hemenway D, et al. Intimate partner violence functions as both a
500 risk marker and risk factor for women's HIV infection: findings from Indian husband-wife dyads. J Acquir
501 Immune Defic Syndr. 2009;51:593-600.

43. UNAIDS. Democratic Republic of the Congo. Country. 2020 Available online:
https://www.unaids.org/en/regionscountries/ countries/democraticrepublicofthecongo (accessed on 28
November 2021.

Kashosi TM, Mutendela JK, Mwenebitu D L, Maotela JK, & Mubagwa K. Assissent of virological
quality of transfused blood in the town of Bukavu, South Kivu, Democratic Republic of Congo. The Pan
African medical journal vol. 30 193. July the 4th, 2018; doi:10.11604/pamj.2018.30.193.13457

508 45. Salamander Trust, Athena, ONUSIDA, AIDS Legal Network, Projet Empower, HEARD,
509 Université du KwaZulu-Natal. Action reliant les initiatives sur la violence à l'égard des femmes et le VIH
510 partout, cadre ALIV(H)E. 2017.

46. Nduwimana, Françoise. Le droit de survivre: Femmes, violence sexuelle et VIH/SIDA. Droits et
Démocratie= Rights & Democracy, Centre international des droits de la personne et du développement
démocratique= International Centre for Human Rights and Democratic Development, 2004.

47. UNAIDS, UNESCO, UNFPA, UNHCR and ILO. Evaluation Offices jointly managed an evaluation of the work of the Joint Programme on preventing and responding to violence against women and girls (VAWG) in all their diversity 2021 available at http://www.unaids.org/en/whoweare/evaluation.

517 48. UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/)

518 49. UNAIDSdata2021(https://www.unaids.org/sites/default/files/media.asset/JC3032_AIDS

519 Data_book_2021)

520 50. Manguro, Griffins O, et al. "HIV infections among female sex workers in Mombasa, Kenya: 521 current prevalence and trends over 25 years." International journal of STD & AIDS 31.14. 2020;1389-522 1397.

523 51. Pettifor AE, van der Straten A, Dunbar MS, Shiboski SC, Padian NS. Early age of first sex: a 524 risk factor for HIV infection among women in Zimbabwe. AIDS. 2004;18(10):1435-1442

525 52. Senn T, Carey M, Vanable P, Coury-Doniger P, Urban M. Characteristics of sexual abuse in 526 childhood and adolescence influence sexual risk behavior in adulthood. Arch Sex Behav. 527 2007;36(5):637-64

528 53. Fisher JC, Cook PA, Kapiga SH. Alcohol use before sex and HIV risk: situational characteristics 529 of protected and unprotected encounters among high-risk African women. Sex Transm Dis. 530 2010;37(9):571-578.

531 54. Maganja RK, Maman S, Groves A, Mbwambo JK. Skinning the goat and pulling the load:
532 transactional sex among youth in Dar es Salaam, Tanzania. AIDS Care. 2007;19(8):974-981

533 55. UNDP. Understanding and Acting on Critical Enablers and Development Synergies for Strategic
534 Investments. New York, NY: United Nations Development Programme; 2012.

535 56. Bell TG, Makondo E, Martinson NA, Kramvis A Hepatitis B Virus Infection in Human 536 Immunodeficiency Virus Infected Southern African Adults: Occult or Overt – That Is the Question. PLoS

- 537 ONE. 2012;7(10): e45750. doi:10.1371/journal.pone.0045750.
- 538 57. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev. 2007;9:25-39
- 539 58. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6-S9
- 540 59. Likhitsup A, Lok AS. Understanding the Natural History of Hepatitis B Virus Infection and the
- 541 New Definitions of Cure and the Endpoints of Clinical Trials. Clin. Liver Dis. 2019;23:401-416. doi:
- 542 10.1016/j.cld.2019.04.002
- 543 60. Terrault NA, Lok ASF, McMahon BJ, Chang K.-M, Hwang JP, Jonas MM, Brown RS, et al.
- 544 Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B 545 guidance. Hepatology. 2018;67, 1560-1599.
- 546 61. EASL EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection.
- 547 J. Hepatol. 2017;67:370-398. doi: 10.1016/j.jhep.2017.03.021.
- 548 62. Stene-Johansen K, Yaqoob N, Overbo J, Aberra H, Desalegn H, Berhe N, et al. Dry Blood
 549 Spots a Reliable Method for Measurement of Hepatitis B Viral Load in Resource-Limited Settings. PLoS
 550 One. 2016 Nov 7;11(11):e0166201. doi: 10.1371/journal.pone.0166201
- 551 63. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661552 2.10.1002/hep.23190.